KR20170020463A - Ezh2 저해제에의 반응에 대한 바이오마커 - Google Patents

Ezh2 저해제에의 반응에 대한 바이오마커 Download PDF

Info

Publication number
KR20170020463A
KR20170020463A KR1020177001353A KR20177001353A KR20170020463A KR 20170020463 A KR20170020463 A KR 20170020463A KR 1020177001353 A KR1020177001353 A KR 1020177001353A KR 20177001353 A KR20177001353 A KR 20177001353A KR 20170020463 A KR20170020463 A KR 20170020463A
Authority
KR
South Korea
Prior art keywords
cancer
bap1
biomarker
expression
ezh2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020177001353A
Other languages
English (en)
Korean (ko)
Inventor
로스 레바인
린제이 라파브
오마르 압델-와합
Original Assignee
메모리얼 슬로안-케터링 캔서 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메모리얼 슬로안-케터링 캔서 센터 filed Critical 메모리얼 슬로안-케터링 캔서 센터
Publication of KR20170020463A publication Critical patent/KR20170020463A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)
    • G01N2333/91017—Methyltransferases (general) (2.1.1.) with definite EC number (2.1.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020177001353A 2014-06-19 2015-06-19 Ezh2 저해제에의 반응에 대한 바이오마커 Abandoned KR20170020463A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462014594P 2014-06-19 2014-06-19
US62/014,594 2014-06-19
PCT/US2015/036677 WO2015196064A1 (en) 2014-06-19 2015-06-19 Biomarkers for response to ezh2 inhibitors

Publications (1)

Publication Number Publication Date
KR20170020463A true KR20170020463A (ko) 2017-02-22

Family

ID=54936135

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177001353A Abandoned KR20170020463A (ko) 2014-06-19 2015-06-19 Ezh2 저해제에의 반응에 대한 바이오마커

Country Status (15)

Country Link
US (1) US20170138946A1 (OSRAM)
EP (1) EP3158086B1 (OSRAM)
JP (1) JP6684230B2 (OSRAM)
KR (1) KR20170020463A (OSRAM)
CN (1) CN106795561B (OSRAM)
AU (1) AU2015276899B2 (OSRAM)
BR (1) BR112016029911A2 (OSRAM)
CA (1) CA2952285A1 (OSRAM)
EA (1) EA036889B1 (OSRAM)
ES (1) ES2870096T3 (OSRAM)
IL (1) IL249443B (OSRAM)
MX (1) MX384423B (OSRAM)
SG (2) SG11201610610YA (OSRAM)
WO (1) WO2015196064A1 (OSRAM)
ZA (1) ZA201608555B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102021642B1 (ko) 2012-10-15 2019-09-16 에피자임, 인코포레이티드 암을 치료하는 방법
CN108025191A (zh) 2015-08-24 2018-05-11 Epizyme股份有限公司 治疗癌症的方法
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
JP7336193B2 (ja) * 2016-02-16 2023-08-31 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ 原発性胃腺癌の体細胞プロモーター特性を明らかにするエピゲノムプロファイリング
GB201615842D0 (en) * 2016-09-16 2016-11-02 Ucl Business Plc Cell death biomarker
CN106963765B (zh) * 2017-03-28 2020-04-07 上海交通大学医学院附属第九人民医院 Ezh2抑制剂化合物在制备治疗眼部黑色素瘤的药物中的应用
WO2020247130A1 (en) * 2019-06-03 2020-12-10 Icahn School Of Medicine At Mount Sinai Compounds and methods for inhibiting cancers via rest inhibition
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
CN118161615B (zh) * 2024-03-19 2025-08-12 山东大学齐鲁医院 Phf20抑制剂在制备抗皮肤癌药物中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US548257A (en) 1895-10-22 Hay rake and loader
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
WO1992010588A1 (en) 1990-12-06 1992-06-25 Affymax Technologies N.V. Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides
US6379897B1 (en) 2000-11-09 2002-04-30 Nanogen, Inc. Methods for gene expression monitoring on electronic microarrays
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US5932422A (en) * 1997-11-14 1999-08-03 Millennium Pharmaceuticals, Inc. Modulation of drug resistance via ubiquitin carboxy-terminal hydrolase
US6218114B1 (en) 1998-03-27 2001-04-17 Academia Sinica Methods for detecting differentially expressed genes
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
US7429466B2 (en) 2000-01-24 2008-09-30 Hypromatrix, Inc Methods and arrays for detecting biological molecules
WO2001055454A1 (en) 2000-01-28 2001-08-02 Althea Technologies, Inc. Methods for analysis of gene expression
WO2002086168A1 (en) 2001-04-19 2002-10-31 Ciphergen Biosystems, Inc. Biomolecule characterization using mass spectrometry and affinity tags
WO2003070887A2 (en) 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2001286171B2 (en) 2001-05-25 2008-01-10 Serono Genetics Institute S.A. Human CDNAs and proteins and uses thereof
US7112408B2 (en) 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
EP1425695A2 (en) 2001-08-13 2004-06-09 Beyong Genomics, Inc. Method and system for profiling biological systems
US20030215858A1 (en) 2002-04-08 2003-11-20 Baylor College Of Medicine Enhanced gene expression system
WO2003091735A1 (en) 2002-04-23 2003-11-06 Millipore Corporation Sample preparation of biological fluids for proteomic applications
WO2007001986A2 (en) 2005-06-20 2007-01-04 Yuling Luo Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations
US20110251216A1 (en) 2010-02-19 2011-10-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
AU2011298987B2 (en) 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
AU2012364924A1 (en) * 2011-02-16 2013-09-12 Medical University Of Graz BAP1 mutational analysis in determining susceptibility to, prognosis of, and treatment of melanocytic neoplasia
WO2012144220A1 (en) * 2011-04-22 2012-10-26 Oncotherapy Science, Inc. Ezh2 as target gene for cancer therapy and diagnosis
BR112014007603A2 (pt) * 2011-09-30 2017-06-13 Glaxosmithkline Llc métodos de tratamento do câncer
HUE042271T2 (hu) 2012-03-12 2019-06-28 Epizyme Inc Emberi EZH2 inhibitorai és azok alkalmazási eljárásai
KR102021642B1 (ko) 2012-10-15 2019-09-16 에피자임, 인코포레이티드 암을 치료하는 방법

Also Published As

Publication number Publication date
BR112016029911A2 (pt) 2017-10-24
EP3158086A1 (en) 2017-04-26
SG10202007972SA (en) 2020-10-29
AU2015276899B2 (en) 2021-08-12
SG11201610610YA (en) 2017-01-27
EP3158086A4 (en) 2018-01-10
CA2952285A1 (en) 2015-12-23
EP3158086B1 (en) 2021-03-24
JP2017525337A (ja) 2017-09-07
AU2015276899A1 (en) 2017-01-05
MX384423B (es) 2025-03-14
US20170138946A1 (en) 2017-05-18
ES2870096T3 (es) 2021-10-26
EA201692497A1 (ru) 2017-06-30
JP6684230B2 (ja) 2020-04-22
EA036889B1 (ru) 2021-01-12
CN106795561A (zh) 2017-05-31
IL249443A0 (en) 2017-02-28
MX2016017097A (es) 2017-05-01
ZA201608555B (en) 2022-05-25
WO2015196064A1 (en) 2015-12-23
IL249443B (en) 2022-05-01
CN106795561B (zh) 2021-04-16

Similar Documents

Publication Publication Date Title
Fan et al. CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer
JP6684230B2 (ja) Ｅｚｈ２阻害剤への応答についてのバイオマーカー
Song et al. Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression
Choi et al. YAP/TAZ initiates gastric tumorigenesis via upregulation of MYC
Shang et al. ID1 expressing macrophages support cancer cell stemness and limit CD8+ T cell infiltration in colorectal cancer
LaFave et al. Loss of BAP1 function leads to EZH2-dependent transformation
CN103026227B (zh) 新的卵巢癌生物标志物和靶
Li et al. UHRF2 promotes intestinal tumorigenesis through stabilization of TCF4 mediated Wnt/β‐catenin signaling
Khammanivong et al. Involvement of calprotectin (S100A8/A9) in molecular pathways associated with HNSCC
US11707481B2 (en) Compositions and methods of treating Fanconi Anemia
Huang et al. DDB2 is a novel regulator of Wnt signaling in colon cancer
Chen et al. CD146 promotes malignant progression of breast phyllodes tumor through suppressing DCBLD2 degradation and activating the AKT pathway
Shen et al. ALKBH4 functions as a suppressor of colorectal cancer metastasis via competitively binding to WDR5
Horazna et al. Msx1 loss suppresses formation of the ectopic crypts developed in the Apc-deficient small intestinal epithelium
Li et al. BMP suppresses Wnt signaling via the Bcl11b-regulated NuRD complex to maintain intestinal stem cells
Lv et al. Hsa_circ_0058495-mediated IGF2BP2 ubiquitination and m6A modification of MEKK1 promote the progression of PDAC
Zhang et al. An epigenetic pathway regulates MHC-II expression and function in B cell lymphoma models
JP2024509530A (ja) 赤血球障害を治療する方法
St-Laurent Pedneault et al. Regulated expression of a FANCL splicing variant as a potential modifier of DNA repair activity
Kadamb et al. Lineage commitment pathways epigenetically oppose oncogenic Gαq/11-YAP signaling in dormant disseminated uveal melanoma
HK1230671B (en) Biomarkers for response to ezh2 inhibitors
Cui et al. Identification of differentially expressed genes associated with papillary thyroid carcinoma
Raju et al. NFAT2 drives both Orai3 transcription and protein degradation by harnessing the differences in epigenetic landscape of MARCH8 E3 ligase
Wang Role of SETD2 in Kidney Cancer Progression
Liu EZH2 Plays Distinct Roles in Tumor Initiation and Metastasis in Breast Cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170116

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200619

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210716

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220217

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee